Andy Chen
Stock Analyst at Wolfe Research
(3.57)
# 853
Out of 4,915 analysts
38
Total ratings
51.85%
Success rate
7.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Initiates: Outperform | $170 | $105.14 | +61.69% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $45.62 | +7.41% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $16.75 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $36.88 | +49.13% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $50.46 | +20.89% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $12.33 | +70.32% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $24.98 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $29.23 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $9.53 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $13.71 | +45.88% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $21.09 | +132.34% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $15.75 | +20.63% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $16.62 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $598.89 | +16.38% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $339.80 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $77.55 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.81 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $44.07 | +47.49% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $47.72 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $289.88 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.80 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $11.54 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $43.37 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $57.68 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.40 | +49.12% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $469.16 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $105.18 | -60.07% | 1 | Feb 15, 2024 |
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $105.14
Upside: +61.69%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $45.62
Upside: +7.41%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.75
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $36.88
Upside: +49.13%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $50.46
Upside: +20.89%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $12.33
Upside: +70.32%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $24.98
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $29.23
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.53
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $13.71
Upside: +45.88%
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $21.09
Upside: +132.34%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $15.75
Upside: +20.63%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $16.62
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $598.89
Upside: +16.38%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $339.80
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $77.55
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $22.81
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $44.07
Upside: +47.49%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $47.72
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $289.88
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.80
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $11.54
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $43.37
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.68
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.40
Upside: +49.12%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $469.16
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $105.18
Upside: -60.07%